Alivus Life Sciences Ltd reports Q2 FY27 revenue of ₹6,820 million, up 16% YoY, in investor presentation
- EBITDA rose 47% YoY to ₹2,851 million; margin expanded to 41.8% from 33.0% a year earlier.
- Net profit increased 51.3% YoY to ₹1,968 million.
- No exceptional items were reported for the quarter.